<DOC>
	<DOCNO>NCT00281697</DOCNO>
	<brief_summary>This phase III , multicenter , randomize , placebo-controlled , blind trial design evaluate efficacy safety bevacizumab combine standard chemotherapy compare chemotherapy alone subject previously treat metastatic breast cancer .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Bevacizumab Combination With Chemotherapy Previously Treated Metastatic Breast Cancer ( RIBBON 2 )</brief_title>
	<detailed_description>For Outcome Measures except Overall Survival One-year Survival , Time Frame Baseline data cut-off analysis primary Outcome Measure ( 3 year 2 month ) . For Outcome Measures Overall Survival One-year Survival , Time Frame Baseline end study ( 6 year , 7 month ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Signed informed consent form . ≥ 18 year age . Histologically confirm carcinoma breast measurable nonmeasurable metastatic disease progress ( patient history brain metastasis eligible study participation [ USA ] , long brain metastasis treat evidence progression hemorrhage treatment ongoing requirement dexamethasone ) . Progression disease follow administration one ( noninvestigational ) chemotherapy regimen administer firstline setting . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . For woman childbearing potential , use effective mean nonhormonal contraception . Life expectancy ≥ 3 month . Willingness capacity comply study followup procedure . Prior hormonal therapy treatment metastatic disease without chemotherapy . Patients must receive chemotherapy metastatic disease firstline set . Hormone therapy alone allow . For subject receive prior anthracyclinebased therapy , documentation leave ventricular ejection fraction &lt; 50 % either multiple gated acquisition ( MUGA ) echocardiogram ( ECHO ) . Treatment one prior cytotoxic regimen metastatic breast cancer ( MBC ) . HER2positive status ( patient unknown HER2 status , determination HER2 status possible , eligible study ) . Unknown estrogen receptor ( ER ) progesterone receptor ( PR ) status . Radiation therapy palliation brain metastasis , biologic therapy , chemotherapy MBC within 21 day prior Day 0 ( Day 1 Cycle 1 treatment ) . Prior therapy bevacizumab vascular endothelial growth factor ( VEGF ) pathwaytargeted therapy . Untreated brain metastasis . Inadequately controlled hypertension . Unstable angina . New York Heart Association Grade II great congestive heart failure ( CHF ) . History myocardial infarction within 6 month prior Day 0 ( day first bevacizumab/placebo infusion ) . History stroke transient ischemic attack within 6 month prior Day 0 . Clinically significant peripheral vascular disease . Evidence bleed diathesis coagulopathy . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 ; anticipation need major elective surgical procedure study . Minor surgical procedure , fineneedle aspiration , core biopsy within 7 day prior Day 0 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 . Serious , nonhealing wound , ulcer , bone fracture . History anaphylactic reaction monoclonal antibody therapy control treatment premedication . History malignancy within 5 year Day 0 , except tumor negligible risk metastasis death , adequately control basal cell carcinoma squamous cell carcinoma skin carcinoma situ cervix . inadequate organ function . Pregnancy ( positive serum pregnancy test ) lactation . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render subject high risk treatment complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Ribbon 2</keyword>
	<keyword>Avastin</keyword>
	<keyword>MBC</keyword>
	<keyword>Breast cancer</keyword>
</DOC>